Insights on Clinical Trials

  1. 5 Operational Gaps To Avoid CGT Patient Risks 5/27/2026

    Examine five critical supply chain gaps in cell and gene therapy logistics that put patients at risk, from invisible operational burdens to reactive monitoring and fragmented coordination strategies.

  2. Navigating The Challenges Of Large, International Phase III Breast Cancer Trials 5/27/2026

    In the competitive landscape of breast cancer research, aligning biomarker testing, regulatory pathways, and regional operations from day one creates a path to faster enrollment and stronger outcomes.

  3. DPCR, qPCR, And RT-qPCR: Advantages And Challenges In Development 5/27/2026

    Discover how the right PCR strategy, combined with thoughtful assay design and validation, can strengthen confidence in your molecular research and clinical testing workflows.

  4. The ctDNA Clinical Trial Advantage 5/27/2026

    See how CROs are helping shape the future of ctDNA research—translating emerging data, regulatory insights, and biomarker innovation into faster, smarter oncology development.

  5. Mergers And Acquisitions: How Institutional Knowledge Protecting Value 5/27/2026

    M&A transitions can either preserve momentum or create costly setbacks. Learn how protecting institutional knowledge helps sponsors reduce risk, maintain continuity, and accelerate development.

  6. De-Risking The Neurology IND: Lessons From Early FDA Engagement 5/27/2026

    Learn how early FDA alignment can help your neurology program move forward with greater clarity, confidence, and regulatory readiness.

  7. Relieving Pressure During Preparation Of A High-Volume sNDA 5/27/2026

    Managing a complex sNDA under pressure? See how one sponsor achieved an early FDA submission through coordinated publishing, regulatory strategy, and flawless execution.

  8. Supporting Global Approval Of A First-In-Class Gene Therapy For A Rare Genetic Disorder 5/27/2026

    Global approvals for a first-in-class gene therapy don’t happen by chance. See how adaptive oversight and inspection readiness kept a complex rare disease program moving forward.

  9. Building A Competitive, Patient‑First Future For Rare Diseases In Europe 5/22/2026

    The EURORDIS Round Table shows how Europe can align regulatory reform and patient-centered design to strengthen competitiveness and improve access to rare disease innovation across Member States.

  10. Debunking Regulatory Myths In CGT Orphan Drug Development 5/22/2026

    We have debunked five common myths that cell and gene therapy developers believe about regulatory expectations for orphan drugs.